Moderna (MRNA) Debt Ratio (2025 - 2026)

Moderna's (MRNA) quarterly Debt Ratio came in at 0.05 in Q2 2026, up 4.99% quarter-over-quarter from 0.05 in Q1 2026.

Analysis

Moderna (MRNA) Debt Ratio (2025 - 2026) Analysis & Trends

Moderna (MRNA) has reported Debt Ratio for 2 consecutive years, with 0.05 the latest figure, recorded in Q2 2026.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.05 in Q2 2026; TTM through Jun 2026 was 0.05, a N/A change from a year earlier, with the FY2025 full-year figure at 0.05, changed N/A from the prior year.
Debt Ratio was 0.05 for Q2 2026 at Moderna, up from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 0.05 in Q2 2026 and troughed at 0.05 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	0.66
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	0.58
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	0.05
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	0.05
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	0.25
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Insmed	27.67 Bn	26.51 Bn	358.27 Mn	0.26

Historic Data

Download Data